secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-067013
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4DMT Q1 net loss $48M; initiates 4D-150 Phase 3 in wet AMD; cash runway to 2028
-------------------------------------------------------------------------------

- Net loss $48.0M vs $32.4M YoY; R&D expenses $40.7M (+46% YoY) due to Phase 3 startup.
- Cash $458M (down from $505M Dec 2024); expected to fund operations into 2028.
- First patients enrolled in 4D-150 Phase 3 (4FRONT-1) in wet AMD; 4FRONT-2 starts Q3 2025; topline H2 2027.
- FDA RMAT designation for 4D-150 in DME; FDA aligned on single Phase 3 trial for BLA.
- Pipeline focused on 4D-150 and 4D-710; paused/terminated 4D-175, 4D-725, 4D-310, 4D-110, 4D-125.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000095017025067013/0000950170-25-067013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000095017025067013/fdmt-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-067013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer